Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Resectable Pancreatic Carcinoma × paricalcitol × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7 Resectable Pancreatic Carcinoma 1 Rectal Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Adenocarcinoma of the Pancreas 1 Adenocarcinoma 1

Interventions

pembrolizumab 1 paricalcitol 1 X-Rays 1 Taxes 1 Specimen Handling 1 Pancreatectomy 1 Hemoglobins 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02930902 2023-02-09

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 1 Completed

Gastrointestinal

Resectable Pancreatic Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡